Related references
Note: Only part of the references are listed.Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers
Nienke M. A. Idzerda et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis
Tadashi Toyama et al.
DIABETES OBESITY & METABOLISM (2019)
Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
Anja Schork et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Proteasuria-The impact of active urinary proteases on sodium retention in nephrotic syndrome
Ferruh Artunc et al.
ACTA PHYSIOLOGICA (2019)
Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension Results From the Randomized, Placebo-Controlled SACRA Study
Kazuomi Kario et al.
CIRCULATION (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Day-by-Day Variability of Home Blood Pressure and Incident Cardiovascular Disease in Clinical Practice: The J-HOP Study (Japan Morning Surge-Home Blood Pressure)
Satoshi Hoshide et al.
HYPERTENSION (2018)
SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
M. V. Karg et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Seasonal variation in nocturnal home blood pressure fall: the Nagahama study
Yasuharu Tabara et al.
HYPERTENSION RESEARCH (2018)
Prognostic significance of day-by-day variability of home blood pressure on progression to macroalbuminuria in patients with diabetes
Emi Ushigome et al.
JOURNAL OF HYPERTENSION (2018)
Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice
Shinji Tanaka et al.
KIDNEY INTERNATIONAL (2018)
SGLT2 inhibitors and the kidney: Effects and mechanisms
V. Tsimihodimos et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2018)
Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
Hiddo J. L. Heerspink et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis
Wenying Yang et al.
JOURNAL OF DIABETES (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
David Z. I. Cherney et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes
Shin Kawasoe et al.
BMC PHARMACOLOGY & TOXICOLOGY (2017)
Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes
Li Tang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2017)
Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study
Hiroshi Tobita et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2017)
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
Anna Solini et al.
CARDIOVASCULAR DIABETOLOGY (2017)
The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients
Sergei I. Petrykiv et al.
DIABETES OBESITY & METABOLISM (2017)
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial
Daisuke Ito et al.
DIABETES CARE (2017)
Diabetes and Hypertension: A Position Statement by the American Diabetes Association
Ian H. de Boer et al.
DIABETES CARE (2017)
Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
Fumika Shigiyama et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring - The NOCTURNE Study -
Kazuomi Kario et al.
CIRCULATION JOURNAL (2017)
Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function
Sergei Petrykiv et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Honghong Zou et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis
Michael Pfeifer et al.
CARDIOVASCULAR DIABETOLOGY (2017)
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
Christian Ott et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade
Michael A. Weber et al.
BLOOD PRESSURE (2016)
Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension
Raymond R. Townsend et al.
JOURNAL OF CLINICAL HYPERTENSION (2016)
Effect of single-pill irbesartan/amlodipine combination-based therapy on clinic and home blood pressure profiles in hypertension with chronic kidney diseases
Ryu Kobayashi et al.
CLINICAL AND EXPERIMENTAL HYPERTENSION (2016)
Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
H. J. L. Heerspink et al.
DIABETES OBESITY & METABOLISM (2016)
Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications
Caroline Pereira Domingueti et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2016)
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
Xinfang Xie et al.
LANCET (2016)
Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants
Bin Zhou et al.
LANCET (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
Michael A. Weber et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Validation of two automatic devices: Omron HEM-7252G-HP and Omron HEM-7251G for self-measurement of blood pressure according to the European Society of Hypertension International Protocol revision 2010
Hakuo Takahashi et al.
BLOOD PRESSURE MONITORING (2015)
Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension
N. B. Amin et al.
DIABETES OBESITY & METABOLISM (2015)
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
R. Chilton et al.
DIABETES OBESITY & METABOLISM (2015)
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
B. Bode et al.
DIABETES OBESITY & METABOLISM (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Ilkka Tikkanen et al.
DIABETES CARE (2015)
The Prevalence and Management of Diabetic Nephropathy in Asia
Yasuhiko Tomino et al.
KIDNEY DISEASES (2015)
Meta-Analysis of the Quantitative Relation Between Pulse Pressure and Mean Arterial Pressure and Cardiovascular Risk in Patients With Diabetes Mellitus
Satoru Kodama et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
Anthony H. Barnett et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Double Product Reflects the Predictive Power of Systolic Pressure in the General Population: Evidence from 9,937 Participants
Rudolph Schutte et al.
AMERICAN JOURNAL OF HYPERTENSION (2013)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
J-F Yale et al.
DIABETES OBESITY & METABOLISM (2013)
The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease
Mai Yanagi et al.
HYPERTENSION RESEARCH (2013)
L/N-Type Calcium Channel Blocker Cilnidipine Added to Renin-Angiotensin Inhibition Improves Ambulatory Blood Pressure Profile and Suppresses Cardiac Hypertrophy in Hypertension with Chronic Kidney Disease
Tomohiko Kanaoka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide
John Powles et al.
BMJ OPEN (2013)
Home Blood Pressure Monitoring Is Better Predictor of Cardiovascular Disease and Target Organ Damage than Office Blood Pressure: A Systematic Review and Meta-Analysis
Sandra C. Fuchs et al.
CURRENT CARDIOLOGY REPORTS (2013)
Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial
John P. H. Wilding et al.
ANNALS OF INTERNAL MEDICINE (2012)
Relationship of Ambulatory Blood Pressure and the Heart Rate Profile with Renal Function Parameters in Hypertensive Patients with Chronic Kidney Disease
Tomohiko Kanaoka et al.
CLINICAL AND EXPERIMENTAL HYPERTENSION (2012)
Oxidative Stress in Obesity and Metabolic Syndrome in Children and Adolescents
Maria Felicia Faienza et al.
HORMONE RESEARCH IN PAEDIATRICS (2012)
Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS)
S. Katayama et al.
DIABETOLOGIA (2011)
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials
Frank A. Holtkamp et al.
EUROPEAN HEART JOURNAL (2011)
The coefficient variation of home blood pressure is a novel factor associated with macroalbuminuria in type 2 diabetes mellitus
Emi Ushigome et al.
HYPERTENSION RESEARCH (2011)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
N. Sarwar et al.
LANCET (2010)
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Seiichi Matsuo et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Plasmin in Nephrotic Urine Activates the Epithelial Sodium Channel
Per Svenningsen et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Day-by-Day Variability of Blood Pressure and Heart Rate at Home as a Novel Predictor of Prognosis The Ohasama Study
Masahiro Kikuya et al.
HYPERTENSION (2008)
Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes
Shin-ichi Araki et al.
DIABETES (2007)
Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease
R Agarwal et al.
KIDNEY INTERNATIONAL (2006)
Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease
R Agarwal et al.
KIDNEY INTERNATIONAL (2006)
Superiority of ambulatory over clinic blood pressure measurement in predicting mortality - The Dublin Outcome Study
E Dolan et al.
HYPERTENSION (2005)
Salt sensitivity of Japanese from the viewpoint of gene polymorphism
T Katsuya et al.
HYPERTENSION RESEARCH (2003)
Share Paper
